藥品和診斷技術配合的有效企業合作的策略 是由出版商Business Insights在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 100 價格從美金3835起跳。
本報告提供醫藥品及診斷技術的不同行業的公司之間所採用的各種各樣的在合作模式為焦點，分就案例研究的風險與回歸中，合作關係的企業所面臨的難題和選擇合作夥伴時的應該考慮的係數，合作契約時的最好實施法相關建議彙整，為您概述為以下內容。
摘要整理
- 個人化的醫藥範例
- 共同開發夥伴關係
- 溯及型開發合作
- 變化形夥伴關係模式
- 處方·診斷合作的最好實施法
- 今後的處方·診斷夥伴關係影響趨勢
關於作者
個人化的醫藥範例
- 摘要
- 簡介
- 處方·診斷夥伴關係的推動因素
- 不同的產業部門的收斂
- 合作趨勢
- 報告的範圍
共同開發夥伴關係
- 摘要
- 簡介
- Genentech/Dako:Herceptin/HercepTest
- Pfizer/Monogram Biosciences::Selzentry/Trofile
- Plexxikon/Roche: Zelboraf/BRAF試驗
- Bayer Schering/Prometheus
- Novartis/Invivoscribe:midostaurin/FLT3
溯及型開發合作
- 摘要
- 簡介
- Vectibix/Erbitux:KRAS
- Iressa(AstraZeneca)/Qiagen
- ■變化形夥伴關係模式
- 摘要
- 簡介
- Prometheus/Entocort
- 武田藥品/Zinfandel:PIOGLITAZONE/TOMM40分析樣品
- GSK/Enigma Diagnostics
- Dako/Quintiles
- Medco/MolecularMD
處方·診斷合作的最好實施法
- 摘要
- 簡介
- 製藥公司尋求的東西
- 診斷技術企業尋求的東西
- 交易談判
- 富有成效的互利合作的組成因素
- 儘早開始
- 共同的目標
- 不同的經營模式的互相理解
- 風險的理解
- 適當的工作流程
- 報酬
- 商業化
今後的處方·診斷夥伴關係影響趨勢
- 摘要
- 簡介
- 產業動態
- 發揮主導作用的調整機關
- 價格設定及報酬環境
- 附錄
- 參考文獻·資料
- 語彙
Description
INTRODUCTION
This report examines the various models that are being adopted by players and uses case studies to highlight the risks and rewards of different approaches to partnerships. The challenges facing companies when entering into a collaboration and factors that should be taken into account when selecting a partner are reviewed and recommendations given as to best practices in partnering.
FEATURES AND BENEFITS
- With the use of case studies understand the various approaches to pharma-diagnostic collaboration and decide the best fit for your company.
- Evaluate the benefits and disadvantages of emerging business models and collaborative agreements for drug diagnostic co-development.
- Evaluate alternative partnership models that can drive revenue growth for both diagnostic and pharma players.
- Understand regulatory trends that will influence the reimbursement status of both the drug and diagnostic in any combined offering.
- Learn how to get the most out of a deal from both the pharma and the diagnostic company's perspective.
HIGHLIGHTS
The need for tropism testing to select patients for Pfizer's maraviroc, prompted a co-development collaboration with Monogram Biosciences, that's laboratory-developed test was the only clinically validated tropism assay. The partnership underlines the need for education of physicians and the role of guidelines to support use of the assay.
Prometheus achieved a five-fold increase in sales in six years for AstraZeneca's treatment for Crohn's disease, Entocort EC, by promoting its IBD serology test in conjunction with the therapy. The sales and marketing model focused on both diagnosis and treatment of irritable bowel disease, an area in which differential diagnosis is difficult.
Entering into a partnership early will facilitate a coordinated approach to simultaneous approval and availability of the Rx and companion Dx. Formal working processes and dedicated project teams engender transparency and good communication channels between both partners.
YOUR KEY QUESTIONS ANSWERED
- What are the different approaches to forming alliances between diagnostic and pharma companies and which have proved most successful and why?
- What are the main challenges in forming alliances between pharma and diagnostic companies and how can these be overcome?
- How can both the diagnostic and pharmaceutical company ensure that they benefit from any alliance?
- How can I form successful alliances with non-traditional partners such as contract research organizations and pharmacy benefit managers?
- How should I go about gaining reimbursement for my diagnostic test?
Table of Contents
Executive Summary
- The personalized medicine paradigm
- Co-development partnerships
- Retrospective development alliances
- Alternative partnership models
- Best practices in RxDx partnering
- Future trends influencing RxDx partnerships
About the author
The personalized medicine paradigm
- Summary
- Introduction
- Drivers of Rx/Dx partnerships
- Regulatory drivers
- EU regulatory initiatives
- A convergence of different industry sectors
- Partnership trends
- Scope of report
Co-development partnerships
- Summary
- Introduction
- Genentech/Dako: Herceptin/HercepTest
- The partnership
- The results
- Observations
- Pfizer/Monogram Biosciences: Selzentry/Trofile
- The partnership
- Results
- Observations
- Plexxikon/Roche: Zelboraf/BRAF test
- The partnership
- Results
- Observations
- Bayer Schering/Prometheus
- The partnership
- Observations
- Novartis/Invivoscribe: midostaurin/FLT3
- The partnership
- Observations
Retrospective development alliances
- Summary
- Introduction
- Vectibix/Erbitux:KRAS
- The partnerships
- Observations
- Iressa (AstraZeneca)/Qiagen
- The partnership
- Observations
Alternative partnership models
- Summary
- Introduction
- Prometheus/Entocort
- The partnership
- The results
- Observations
- Takeda/Zinfandel: pioglitazone/TOMM40 assay
- Background
- The partnership
- Observations
- GSK/Enigma Diagnostics
- The partnership
- Observations
- Dako/Quintiles
- Background
- The partnership
- Observations
- Medco/MolecularMD
- The partnership
- Observations
Best practices in RxDx partnering
- Summary
- Introduction
- What are pharma companies looking for?
- What are Dx companies looking for?
- Negotiating the deal
- Ingredients of a successful relationship
- Start early
- Sharing a common goal
- Mutual understanding of different business models
- Understanding risks
- Good working processes
- Reimbursement
- Commercialization
Future trends influencing RxDx partnerships
- Summary
- Introduction
- Industry dynamics
- Regulators take proactive role
- Pricing and reimbursement environment
- UK Stratified Medicine initiative
- Appendix
- Bibliography/References
- Abbreviations
